Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Johnson & Johnson) Oct 17, 2014 - Janssen-Cilag International NV announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor.
read corporate press release »
(PharmaTimes [UK]) Oct 17, 2014 - Novartis’ stomach tumour therapy Glivec (imatinib) is a giant leap closer to being funded by the NHS in England after cost regulators again endorsed its use.
read article »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.
Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.
Novocure has posted 4 jobs.